AR073514A1 - Metodos de tratamiento de hiperuricemia y estados de enfermedad asociados - Google Patents

Metodos de tratamiento de hiperuricemia y estados de enfermedad asociados

Info

Publication number
AR073514A1
AR073514A1 ARP090103535A ARP090103535A AR073514A1 AR 073514 A1 AR073514 A1 AR 073514A1 AR P090103535 A ARP090103535 A AR P090103535A AR P090103535 A ARP090103535 A AR P090103535A AR 073514 A1 AR073514 A1 AR 073514A1
Authority
AR
Argentina
Prior art keywords
hyperuricemia
dosage form
renal
uric acid
gout
Prior art date
Application number
ARP090103535A
Other languages
English (en)
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of AR073514A1 publication Critical patent/AR073514A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente revelacion se refiere a composiciones y métodos para reducir los niveles de ácido urico en un individuo necesitado de dicho tratamiento. También se refiere al tratamiento de la hiperuricemia y de enfermedades asociadas con niveles elevados de ácido urico en mamíferos mediante el uso scilo-inositol. Reivindicacion 2: El método de la reivindicacion 1, donde el scilo-inositol se administra en combinacion con un segundo agente terapéutico. Reivindicacion 6: El método de la reivindicacion 5, donde la afeccion se selecciona de gota, un ataque de gota recurrente; tofos gotosos, artritis gotosa, nefropatía gotosa eclampsia; ateroscleropatía; arterioloscleropatía, síndrome metabolico, enfermedades que implican la formacion y destruccion acelerada de células sanguíneas; hiperuricemia; hiperuricemia cronica de la policitemia vera, de la metaplasma mieloide, o de la discrasia sanguínea, hipertension, enfermedades cardiovasculares, enfermedades coronarias, síndrome de Lesch-Nyhan y Kelley-Seegmiller hasta el punto de síntomas similares a los renales y a los de la gota; enfermedad renal; cálculos renales; insuficiencia renal; insuficiencia renal aguda; inflamacion de las articulaciones; artritis, litiasis urinaria; litiasis de ácido urico; satumismo; hiperparotiroidismo; soriasis y sarcoidosis Reivindicacion 12: El método de la reivindicacion 11, donde la forma de dosificacion unitaria se selecciona de una forma de dosificacion de liberacion inmediata y una forma de dosificacion de liberacion extendida.
ARP090103535A 2008-09-15 2009-09-15 Metodos de tratamiento de hiperuricemia y estados de enfermedad asociados AR073514A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9702308P 2008-09-15 2008-09-15

Publications (1)

Publication Number Publication Date
AR073514A1 true AR073514A1 (es) 2010-11-10

Family

ID=41319433

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103535A AR073514A1 (es) 2008-09-15 2009-09-15 Metodos de tratamiento de hiperuricemia y estados de enfermedad asociados

Country Status (9)

Country Link
US (1) US8748496B2 (es)
EP (1) EP2349280B1 (es)
JP (1) JP5685192B2 (es)
AR (1) AR073514A1 (es)
AU (1) AU2009290612B2 (es)
CA (1) CA2737163C (es)
ES (1) ES2521674T3 (es)
TW (1) TW201016208A (es)
WO (2) WO2010031051A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
CA2604399A1 (en) 2005-04-11 2006-10-19 Savient Pharmaceuticals, Inc. Variant forms of urate oxidase and use thereof
US9377454B2 (en) 2009-06-25 2016-06-28 Crealta Pharmaceuticals Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
CN102726721A (zh) * 2011-12-21 2012-10-17 聂存良 一种平衡性的微量元素排铅口服液
US20160303050A1 (en) * 2015-04-20 2016-10-20 Twi Biotechnology, Inc. Formulations containing diacerein and methods of lowering blood levels of uric acid using the same
WO2018089808A1 (en) 2016-11-11 2018-05-17 Horizon Pharma Rheumatology Llc Combination therapies of prednisone and uricase molecules and uses thereof
CN109666687B (zh) * 2018-12-14 2020-08-04 艾美科健（中国）生物医药有限公司 一种生物转化生产鲨肌醇的大肠埃希氏菌工程菌株及其构建方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998485A (en) * 1997-06-16 1999-12-07 Cedars-Sinai Medical Center Method for modulating immune response with inositol
JP2008520589A (ja) * 2004-11-17 2008-06-19 ジョアン マクローリン， シロイノシトール誘導体を含む組成物およびタンパク質凝集障害を治療するための方法
US20080200437A1 (en) * 2006-12-29 2008-08-21 Jean-Marie Lehn Cyclitols and Their Derivatives and Their Therapeutic Applications

Also Published As

Publication number Publication date
JP2012502914A (ja) 2012-02-02
WO2010031061A1 (en) 2010-03-18
ES2521674T3 (es) 2014-11-13
EP2349280B1 (en) 2014-07-30
WO2010031051A1 (en) 2010-03-18
US8748496B2 (en) 2014-06-10
US20100152305A1 (en) 2010-06-17
AU2009290612A1 (en) 2010-03-18
CA2737163C (en) 2019-03-12
AU2009290612B2 (en) 2015-05-14
EP2349280A1 (en) 2011-08-03
JP5685192B2 (ja) 2015-03-18
CA2737163A1 (en) 2010-03-18
TW201016208A (en) 2010-05-01

Similar Documents

Publication Publication Date Title
AR073514A1 (es) Metodos de tratamiento de hiperuricemia y estados de enfermedad asociados
Allinovi et al. Anti-fibrotic treatments: a review of clinical evidence
AR059575A1 (es) Metodo para el tratamiento de enfermedades inflamatorias
Konstantinou et al. Pathophysiology-based novel pharmacotherapy for heart failure with preserved ejection fraction
Qu et al. 1, 25 (OH) 2D3 improves cardiac dysfunction, hypertrophy, and fibrosis through PARP1/SIRT1/mTOR‐related mechanisms in type 1 diabetes
CR11749A (es) Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina
DK2437749T3 (da) Kombineret fremgangsmåde til behandling af kræft eller en præcancerøs tilstand
CL2007001993A1 (es) Compuestos derivados de pirimidilciclopentanos hidroxilados y metoxilados; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodegenerat
BRPI0910198A2 (pt) composição para administração a partir de um sítio local de um agente baseado em nucleotídeos e método para tratar um sujeito sofrendo de uma doença requerendo tratamento local com um agente baseado em nucleotídeo.
AR048588A1 (es) Uso de inhibidores de la fosfodiesterasa de tipo iii (pde iii) para la reduccion del tamano del corazon en mamiferos que padecen insuficiencia cardiaca
CL2008002999A1 (es) Uso de una composicion farmeceutica que comprende trns-clominefo para preparar un medicamenteo util en el ratamiento de recuccion de los niveles de glucosa en ayunas en un varon.
BR112014017650A2 (pt) composições e uso de ésteres de forbol
UY29274A1 (es) Composicion farmaceutica para tratar la hipertension, que comprende telmisartano e hidroclorotiazida
AR066168A1 (es) Formulaciones galenicas de compuestos organicos
CL2013000513A1 (es) Uso de una composicion farmaceutica que comprende: a) un compuesto monohidratado formado por dos aniones y un cation o b) valsartan y un etil-ester de acido, para el tratamiento de hipertension y/o la prevencion o el tratamiento de insuficiencia cardiaca en un mamifero que recibe terapia anti-coagulante.
BR112015004012A2 (pt) combinações de inibidores de sglt 2 e fármacos anti-hipertensivos
MX2010010334A (es) Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida.
JP2012502914A5 (es)
Shimamura et al. Irbesartan improves endothelial dysfunction, abnormal lipid profile, proteinuria and liver dysfunction in Zucker diabetic fatty rats independent of glucose and insulin levels
Tanwar et al. Relationship between Diabetes Mellitus and Bone Health–A Review
ECSP10010464A (es) Uso de ranolazina para el tratamiento de enfermedades cardiovasculares
WO2008073466A3 (en) Alpha b-crystallin as a therapy for inflammation
BRPI0607976A2 (pt) composição farmacêutica e uso de uma composição
PE20091885A1 (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de dronedarona
CL2008002278A1 (es) Metodo para el tratamiento de una enfermedad ocular relacionada al tnfalfa; metodo para la atenuacion de la expresion del arnm de tace o tnfr1 en el ojo de un paciente.

Legal Events

Date Code Title Description
FB Suspension of granting procedure